Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory bowel disease
Biotech
Vedanta's live bacteria cocktail fails phase 2 colitis trial
Vedanta is reorienting resources toward lead candidate VE303, which is chasing the tail of Seres’ Vowst in treating recurrent C. diff infections.
Darren Incorvaia
Aug 13, 2025 1:48pm
Lilly inks $50M deal for biotech's FXR program
Feb 26, 2025 5:35am
Sanofi shows how $500M IBD bet compares to Merck, Roche rivals
Feb 24, 2025 8:11am
GI-focused CRO boosts trial tech with adaptive software
Feb 3, 2025 11:40am
Sanofi, Teva tout midstage win for TL1A antibody in Crohn’s, UC
Dec 17, 2024 10:30am
AbbVie acquires oral peptide biotech Nimble for $200M
Dec 13, 2024 10:38am
